ASTRAZENECA PLC reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Cambridge
SEC filing record 1 source field available
Fiscal year end
31 December
ASTRAZENECA PLC has filed 2,050 SEC EDGAR filings since 13 Mar 1995

SEC filing history

Showing 501-525 of 1,000 matching filings.

Per page
25
Current page
21
6-K File 001-11960

ENHERTU IMPROVED PFS IN MBC IN DESTINY-BREAST02

Filing date
15 Aug 2022
Reporting date
15 Aug 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ENHERTU APPROVED IN US FOR HER2-MUTANT NSCLC

Filing date
12 Aug 2022
Reporting date
12 Aug 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ACQUISITION OF TENEOTWO COMPLETED

Filing date
11 Aug 2022
Reporting date
11 Aug 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ENHERTU APPROVED IN THE US FOR HER2-LOW MBC

Filing date
08 Aug 2022
Reporting date
08 Aug 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

LYNPARZA APPROVED IN EU FOR EARLY BREAST CANCER

Filing date
04 Aug 2022
Reporting date
04 Aug 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
01 Aug 2022
Reporting date
01 Aug 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
01 Aug 2022
Reporting date
01 Aug 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
01 Aug 2022
Reporting date
01 Aug 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

CHAIR SUCCESSION

Filing date
29 Jul 2022
Reporting date
29 Jul 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TEZSPIRE RECOMMENDED FOR EU APPROVAL IN ASTHMA

Filing date
25 Jul 2022
Reporting date
25 Jul 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ULTOMIRIS RECOMMENDED FOR EU APPROVAL FOR GMG

Filing date
25 Jul 2022
Reporting date
25 Jul 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ENHERTU GRANTED PRIORITY REVIEW FOR HER2-LOW MBC

Filing date
25 Jul 2022
Reporting date
25 Jul 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ENHERTU APPROVED IN EU FOR HER2-POSITIVE MBC

Filing date
19 Jul 2022
Reporting date
19 Jul 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G File 005-55247

SC 13G filing

Filing date
08 Jul 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA TO ACQUIRE TENEOTWO AND T CELL ENGAGER

Filing date
05 Jul 2022
Reporting date
05 Jul 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
01 Jul 2022
Reporting date
01 Jul 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI IMPROVED PCR IN RESECTABLE LUNG CANCER

Filing date
30 Jun 2022
Reporting date
30 Jun 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
11-K File 001-11960

ANNUAL REPORT

Filing date
29 Jun 2022
Reporting date
31 Dec 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ENHERTU RECOMMENDED FOR BREAST CANCER EU APPROVAL

Filing date
27 Jun 2022
Reporting date
27 Jun 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

LYNPARZA RECOMMENDED IN EU FOR EARLY BREAST CANCER

Filing date
27 Jun 2022
Reporting date
27 Jun 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

EPLONTERSEN PH III TRIAL MET CO-PRIMARY ENDPOINTS

Filing date
21 Jun 2022
Reporting date
21 Jun 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
25-NSE File 001-11960

25-NSE filing

Filing date
10 Jun 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
25-NSE File 001-11960

25-NSE filing

Filing date
09 Jun 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ENHERTU EFFICACY RESULTS IN HER2-LOW BREAST CANCER

Filing date
06 Jun 2022
Reporting date
06 Jun 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .